Global Market Direct’s pharmaceuticals report, “4-Antibody AG - Product Pipeline Review - 2013” provides data on the 4-Antibody AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, 4-Antibody AG’s corporate website, SEC filings, investor presentations and featured press releases, both from 4-Antibody AG and industry-specific third party sources, put together by Global Markets Direct’s team.
- 4-Antibody AG - Brief 4-Antibody AG overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of 4-Antibody AG human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of 4-Antibody AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the 4-Antibody AG’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate 4-Antibody AG’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of 4-Antibody AG in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the 4-Antibody AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with 4-Antibody AG. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of 4-Antibody AG and identify potential opportunities in those areas.
Table Of Contents
4-Antibody AG - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 3 List of Figures 3 4-Antibody AG Snapshot 4 4-Antibody AG Overview 4 Key Information 4 Key Facts 4 4-Antibody AG - Research and Development Overview 5 Key Therapeutic Areas 5 4-Antibody AG - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 4-Antibody AG - Pipeline Products Glance 9 4-Antibody AG - Early Stage Pipeline Products 9 Pre-Clinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 4-Antibody AG - Drug Profiles 11 4Ab-028 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 Antibody Targeting GITR 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 Antibody Targeting OX40 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 Antibody Targeting TIM-3 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 CXCR3 Antibody 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 Drug For AutoImmune Disorders And Inflammation 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 4-Antibody AG - Pipeline Analysis 17 4-Antibody AG - Pipeline Products by Therapeutic Class 17 4-Antibody AG - Pipeline Products By Mechanism of Action 18 4-Antibody AG - Locations And Subsidiaries 19 Head Office 19 Appendix 20 Methodology 20 Coverage 20 Secondary Research 20 Primary Research 20 Expert Panel Validation 20 Contact Us 21 Disclaimer 21
List of Tables
4-Antibody AG, Key Information 4 4-Antibody AG, Key Facts 4 4-Antibody AG - Pipeline by Indication, 2013 6 4-Antibody AG - Pipeline by Stage of Development, 2013 7 4-Antibody AG - Monotherapy Products in Pipeline, 2013 8 4-Antibody AG - Pre-Clinical, 2013 9 4-Antibody AG - Discovery, 2013 10 4-Antibody AG - Pipeline By Therapeutic Class, 2013 17 4-Antibody AG - Pipeline Products By Mechanism of Action, 2013 18
List of Figures
4-Antibody AG - Pipeline by Indication, 2013 6 4-Antibody AG - Pipeline by Stage of Development, 2013 7 4-Antibody AG - Monotherapy Products in Pipeline, 2013 8 4-Antibody AG - Pipeline By Therapeutic Class, 2013 17 4-Antibody AG - Pipeline Products By Mechanism of Action, 2013 18